Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia

Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia - MRD in peripheral blood compared to bone marrow in AML patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52290

Enrollment

151

Registered

2021-07-05

Start date

2021-10-08

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia AML

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Patient with: o a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML), or o acute leukemia*s of ambiguous lineage according to WHO 2008 or o a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score > 4.5 - Treated according to HOVON clinical trials - Age 18 yr or older - A bone marrow aspiration has been scheduled - WHO performance status 0, 1 or 2 - Written informed consent

Exclusion criteria

Exclusion criteria: - Acute promyelocytic leukemia - Pregnant or lactating females - Unwilling or not capable to use effective means of birth control

Design outcomes

Primary

Measure	Time frame
The primary outcome is to compare the prognostic value of MRD in peripheral blood and bone marrow.	—

Secondary

Measure	Time frame
The secondary outcome measure is the amount of leukemic stem cells (LSC) in bone marrow and peripheral blood and the concordance between MRD in PB and BM.	—

Countries

Netherlands

Outcome results